Eczema “Sanofi has reported mixed mid-stage results for its bispecific nanobody lunsekimig—failing in atopic dermatitis while delivering encouraging outcomes across two respiratory indications.
The asset, which targets both thymic stromal lymphopoietin (TSLP) and interleukin-13 (IL-13), demonstrated efficacy in asthma and chronic rhinosinusitis, reinforcing its potential in respiratory disease even as its dermatology ambitions falter.
Strong Performance in Asthma and Rhinosinusitis
In the Phase 2b Aircules trial, lunsekimig met its primary endpoint in patients with moderate-to-severe asthma, achieving a statistically significant reduction in exacerbations over 48 weeks.
Similarly, the Phase 2a Duet study in chronic rhinosinusitis showed the drug met its primary goal, significantly reducing nasal polyps over a 24-week period—an important marker of disease severity and progression.
These results support the therapeutic rationale behind targeting both TSLP and IL-13—key drivers of airway inflammation.
Eczema Setback Highlights Indication Complexity
However, momentum was tempered by disappointing results from the Phase 2b Velvet trial in moderate-to-severe atopic dermatitis. The study failed to meet its primary endpoint of reducing eczema severity, although improvements were observed in secondary measures such as skin clearance.
While Sanofi has not yet released full datasets, it confirmed that lunsekimig was “generally well tolerated” across all three studies, with safety profiles consistent between treatment and placebo arms.
Safety Profile Remains Consistent
Across the respiratory trials, the most common treatment-emergent adverse events (TEAEs) included nasopharyngitis, upper respiratory tract infections, and headaches. Injection site reactions and mild infections were also reported, particularly in the rhinosinusitis study.
Importantly, rates of serious adverse events and discontinuations were comparable between lunsekimig and placebo groups, supporting a favorable tolerability profile.
Strategic Implications for Sanofi’s Pipeline
According to Houman Ashrafian, the data reinforce confidence in lunsekimig’s dual-targeting mechanism for respiratory diseases.
“These data are promising and support our belief that the dual-targeting mechanism of lunsekimig may offer a novel treatment option for patients living with respiratory diseases, including asthma,” he said.
The results arrive at a critical time for Sanofi, which has faced a series of pipeline setbacks and leadership changes in recent months. While the respiratory wins provide validation, the eczema failure raises questions about lunsekimig’s ability to compete in dermatology—particularly as the company seeks a long-term successor to its blockbuster Dupixent.
Competitive Landscape Intensifies
The broader scientific momentum around TSLP targeting continues to build. Competitors are advancing similar approaches, including multi-cytokine inhibitors and next-generation biologics.
Notably, Pfizer has reported Phase 2 success in atopic dermatitis with its IL-4, IL-13, and TSLP-targeting candidate tilrekimig, while other biotech players are progressing anti-TSLP antibodies into late-stage asthma trials.
Outlook: Respiratory Focus Gains Priority
With lunsekimig continuing in Phase 2 trials for high-risk asthma and previously evaluated in Phase 3 chronic obstructive pulmonary disease (COPD) studies, Sanofi appears increasingly likely to prioritize respiratory indications where clinical signals are strongest.
However, the eczema setback underscores a broader challenge in immunology drug development: success in one inflammatory disease does not guarantee efficacy across others—even when driven by overlapping biological pathways.
Eczema Trial Falls Short
Sanofi’s bispecific candidate, lunsekimig, did not meet its primary endpoint in a mid-stage trial targeting Eczema, specifically moderate-to-severe atopic dermatitis. The drug failed to significantly reduce disease severity compared to placebo, marking a notable setback in the competitive Eczema treatment landscape.
Although some secondary improvements were observed, the outcome reinforces how complex and difficult it is to develop effective therapies for Eczema, especially when targeting multiple inflammatory pathways.
Respiratory Trials Deliver Strong Results
In contrast, the same bispecific therapy delivered strong results in respiratory indications. Sanofi reported that the drug met primary endpoints in asthma and chronic rhinosinusitis trials, significantly reducing exacerbations and improving lung function.
These dual successes highlight the drug’s potential beyond Eczema, particularly in diseases driven by inflammatory pathways like TSLP and IL-13.
Understanding the Science Behind the Results
The bispecific antibody targets two key inflammatory drivers, offering a dual mechanism of action. While this approach appears effective in respiratory diseases, its performance in Eczema suggests that the biology of skin inflammation may require different or more targeted strategies.
Experts had already considered the Eczema trial a higher-risk endeavor, given the limited evidence supporting the drug’s mechanism in dermatology compared to respiratory conditions.
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
- Editorial Team
